Indometacin farnesil

Indometacin farnesil
Clinical data
AHFS/Drugs.comInternational Drug Names
Routes of
administration		Oral
ATC code
  • None
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
MetabolismTo indometacin
Elimination half-life1.5 hours
ExcretionRenal
Identifiers
IUPAC name
  • (2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl [1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]acetate
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
ECHA InfoCard100.242.585
Chemical and physical data
FormulaC34H40ClNO4
Molar mass562.15 g·mol−1
3D model (JSmol)
SMILES
  • CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)OCC=C(C)CCC=C(C)CCC=C(C)C
InChI
  • InChI=1S/C34H40ClNO4/c1-23(2)9-7-10-24(3)11-8-12-25(4)19-20-40-33(37)22-30-26(5)36(32-18-17-29(39-6)21-31(30)32)34(38)27-13-15-28(35)16-14-27/h9,11,13-19,21H,7-8,10,12,20,22H2,1-6H3/b24-11+,25-19+ checkY
  • Key:CFIGYZZVJNJVDQ-LMJOQDENSA-N checkY
  (verify)

Indometacin farnesil (INN) is a prodrug of the nonsteroidal anti-inflammatory drug (NSAID) indometacin,[1] designed to reduce the occurrence of side-effects by esterification of the carboxyl group on indometacin with farnesol. Indometacin farnesil was first approved in Japan in 1991, and is available in Japan[2] and Indonesia, under the trade names Infree and Dialon, respectively.

References

  1. ↑ Hirohata S, Yanagida T, Kawai M, Kikuchi H (November 1999). "Inhibition of human B cell activation by a novel nonsteroidal anti-inflammatory drug, indometacin famesil". Immunopharmacology. 44 (3): 245–254. doi:10.1016/S0162-3109(99)00084-3. PMID 10598881.
  2. ↑ "Infree (indometacin farnesil capsules) Full Prescribing Information" (PDF). Eisai Co., Ltd. Archived from the original (PDF) on 2010-12-03. from Eisai Co.
This article is issued from WikiProjectMed. The text is available under Creative Commons Attribution-ShareAlike License unless otherwise noted. Additional terms may apply for the media files.